

Update to the September 2005 Handbook of Limited Use Drug Products. These changes correlate with Edition 39-Update 15 of the ODB Formulary/CDI.

Drug(s)	LU Code	Clinical Criteria/Comments
Aromasin (exemestane)	407	Additional criterion: For the sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy. LU Authorization Period: Treatment period required to complete a total of 5 years of adjuvant therapy.

(Effective March 9, 2007)